Provider Resources to Support Patients

Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care to Improve Outcomes Across the Disease Spectrum

Join us for this educational activity, presented in partnership with PeerView, at the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago and featuring experts Karim Fizazi, MD, PhD; Elena Castro, MD; and Matthew R. Smith, MD, PhD. Learners will hear the most recent evidence supporting clinical decision-making across prostate cancer stages and lines of therapy, along with practical case exercises. This unique symposium will bridge the gap between theory and practice, allowing oncology and urology professionals to rapidly enhance their performance by developing sound, evidence-based protocols for the integration of effective, modern therapeutics into routine patient care. The recorded, enduring activity will be posted here after the live event.

New Treatments on the Horizon: Cancer Conversations on Novel Mechanisms and Emerging Treatment Options in mCRPC

Join us in person at ASCO Chicago or virtually (May 31, 7:00-8:00 pm CT) for this satellite symposium where experts Alicia Morgans, MD, MPH, FASCO; Charles J. Ryan, MD; and Neal Shore, MD, FACS, review novel and emerging treatments and strategies in the management of patients with metastatic castration-resistant prostate cancer (mCRPC), including the mechanism of action and rationale for novel agents and combinations under investigation and emerging data on these approaches and ongoing clinical trials for patients with mCRPC.

Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice

In this on-demand version of an event presented in partnership with PeerView at the 2025 AUA Annual Meeting, an expert faculty panel including Neal D. Shore, MD, FACS; Eleni Efstathiou, MD, PhD; and Stephen Freedland, MD, provides the tools to incorporate modern therapeutics into the care of patients across disease stages. Watch now to learn best practices for identification of biochemically recurrent prostate cancer, implementation of genetic testing, team-based management of AEs, and promoting treatment adherence through patient education. This activity expires May 27, 2026.

Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum

Watch this on-demand session recorded at a live ASCO GU 2025 event, presented in partnership with PeerView. This MasterClass & Practicum activity led by Alicia K. Morgans, MD, MPH, FASCO; Matthew R. Smith, MD, PhD; and Sandy Srinivas, MD, provides learners with the strategies they need to incorporate modern prostate cancer care into practice. The faculty panel pairs a review of the efficacy and safety evidence supporting approved and emerging treatment regimens with discussion of realistic patient cases that illustrate practical approaches for creating individualized treatment plans. This activity expires March 14, 2026.

Navigating Therapeutic Choices in Prostate Cancer: Effective Decision-Making for Patient-Centric Care

This educational activity, presented in partnership with PeerView and based on a recent live symposium at the 2024 Society for Urologic Oncology Annual Meeting, focuses on patient-centric approaches for prostate cancer care. Featuring discussion of real-world cases, led by experts Neal D. Shore, MD, FACS; Gordon A. Brown, DO, FASCO; and Tanya Barauskas Dorff, MD, topics include identification of biochemical recurrence, implementation of genetic testing, team-based management of adverse events, and patient education strategies to optimize treatment adherence. This activity will expire on January 5, 2026.

Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists

This event, brought to you by PeerView and ZERO Prostate Cancer, features experts Brooke Looney, PharmD, CSP and Izabela Mazur, PharmD, BCOP providing insight on the latest evidence on use of PARP inhibition in the treatment of mCRPC and practical guidance on genomic testing, patient education, and team-based toxicity management delivered via realistic patient case discussions. Join this virtual learning opportunity originally presented at the 2024 Joint Federal Pharmacy Seminar. This activity will expire on December 10, 2025.

Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery

This event from ZERO and PeerView was held during the 2024 Nurses Organization of Veterans Affairs Conference. Experts Kassandra August-Marcucio, DNP, APRN, ACNP-BC, SANE and Grace Cullen, DNP, FNP-BC, AOCNP, PMGT-BC, FPCN discussed genomic testing recommendations and nurse-led strategies to optimize the use of PARP inhibitors in veterans with prostate cancer. This activity will expire on November 29, 2025.

Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care

In this educational activity, a panel of experts competes to answer questions on prostate cancer treatment and provide updates on the latest practice-changing data on neoadjuvant, adjuvant, and radioligand immunotherapy in prostate cancer along with an expert-led discussion of the implications for practice. Featuring Karim Fizazi, MD, PhD, Pedro C. Barata, MD, MSc, FACP, Kim N. Chi, MD, FRCPC, and Alicia K. Morgans, MD, MPH, this event was held live at ASCO 2024 in partnership with PeerView. This activity will expire on July 1, 2025.

Advanced Prostate Cancer: Personalized Treatment Plan

Join Shawn Dason, MD; Dakim Gaines, MD, PhD; and Andrew Laccetti, MD, MS to learn about integrating the latest clinical insights into monotherapy and combination treatments for advanced prostate cancer. Hone your skills in developing personalized treatment plans for a diverse range of patients and settings, while integrating a multidisciplinary approach. This activity was developed through a partnership with MedAll. The recording will be active until June 5, 2025.

Advanced Prostate Cancer: Latest Clinical Trials to Treatment Plans

Join Shawn Dason, MD; Dakim Gaines, MD, PhD; and Andrew Laccetti, MD, MS to discover emerging treatments from clinical trials and learn to integrate them into current protocols, enhancing your everyday practice with evidence-based advancements. This activity was developed through a partnership with MedAll. The recording will be active until June 5, 2025.

Use of PARP Inhibitor Plus AR-Signaling Inhibitor Combinations for Patients with mCRPC: A medical oncologist's perspective

In this expert commentary, Rana R. McKay, MD, offers her perspective on how the latest approvals of combination therapy with a PARP inhibitor and an AR-signaling inhibitor will affect treatment choices for patients with mCRPC. Provided by Clinical Care Options, LLC., in partnership with ZERO.

Nursing Support for mCRPC patients during radiopharmaceutical treatment

In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC). Watch the video and download the accompanying slides to learn about: a) the considerations for treatment selection in clinical practice to minimize the impact on patients' lives; b) applying recent data to treatment sequencing in bone-dominant mCRPC; and c) educating and supporting patients during treatment so they know what to expect Provided by COR2ED, in partnership with ZERO.

Treatment intensification in mCSPC: The nurse perspective

In this podcast, oncology nurses Brenda Martone and Jennifer Sutton discuss how to use data to select the most appropriate treatments for patients with metastatic castration-sensitive prostate cancer. They also share the importance of being able to explain these clinical decisions to patients and reassure them that earlier intensive treatment can prolong overall survival without seriously impacting quality of life. Provided by COR2ED, in partnership with ZERO.

Podcast: Which mCSPC patients benefit from early treatment intensification?

In this podcast, you'll hear Dr. Shilpa Gupta, MD and Dr. Fabio Schutz review patient cases to explore which patients with metastatic castration-sensitive prostate cancer (mCSPC) benefit from early treatment intensification. They discuss how to apply key data from ARASENS and PEACE-1 in clinical practice, triplet therapy as the new standard of care, and the patient subgroups that benefit the most from early treatment intensification. Provided by COR2ED, in partnership with ZERO.

The Role of the Nurse in nmCRPC Patient Management

In this video, Research Nurse Coordinator Pablo Peinado discusses selecting treatments for nmCRPC in clinical practice to minimize the impact on the patient's quality of life, and how nurses can support and educate their patients, so they know what to expect during treatment. Provided by COR2ED, in partnership with ZERO.

The purpose of published guidelines are to provide providers and patients with evidence-based and consensus-based best practices for diagnosing, treating, and managing prostate cancer. The American Urologic Association publishes healthcare provider guidelines for early detection, localized prostate cancer, advanced prostate cancer, and radiotherapy.

In addition, the National Comprehensive Cancer Network (NCCN) Guidelines document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes. Patient guidelines are also available through the NCCN.